938-39-6

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromoquinolin-2(1H)-one is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drugs and therapeutic agents. Its unique chemical structure allows for the creation of compounds with specific medicinal properties, enhancing the range of treatments available for various health conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Bromoquinolin-2(1H)-one serves as an intermediate in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products aids in the development of more effective and targeted solutions for pest and weed control, ultimately contributing to increased crop yields and agricultural productivity.
Used in Organic Synthesis:
4-Bromoquinolin-2(1H)-one is utilized as a valuable chemical reagent in organic synthesis, where it plays a crucial role in the formation of complex organic compounds. Its unique properties and reactivity make it an essential component in the synthesis of a wide range of organic molecules, including those with potential applications in various industries.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Bromoquinolin-2(1H)-one is employed as a research compound for exploring its potential biological and medical applications. Studies have investigated its antimicrobial, antiviral, and anti-inflammatory properties, which may lead to the discovery of new treatments for infectious diseases and inflammatory conditions.
Used in Drug Development:
4-Bromoquinolin-2(1H)-one is used in drug development as a starting material or building block for the creation of new pharmaceutical compounds. Its unique structure and properties make it a promising candidate for the development of innovative drugs with improved efficacy and selectivity, ultimately contributing to advancements in healthcare and medicine.

InChI:InChI=1/C9H6BrNO/c10-7-5-9(12)11-8-4-2-1-3-6(7)8/h1-5H,(H,11,12)

Upstream product

• 22614-98-8 4-bromoquinoline-N-oxide 
• 79655-46-2 (2-amino-phenyl)-propiolic acid 
• 70254-43-2 4-Hydroxy-2-quinolone 
• 20151-40-0 2,4-dibromoquinoline 
• 146564-16-1 4-bromo-2-methoxy-quinoline 
• 67-66-3 chloroform 
• 10025-87-3 trichlorophosphate 

Downstream Products

• 120-72-9 indole 

Relevant academic research and scientific papers

Coumarin derivative and analogue, preparation method and application thereof

The invention relates to a coumarin derivative and analogue, a preparation method and application thereof, belongs to the field of chemical medicines, and provides a compound shown as a formula I or apharmaceutically acceptable salt thereof, and a preparation method and application of the compound. According to the invention, biological experiments show that the compound has a strong in-vitro anti-fibrosis effect, can obviously reduce deposition of intercellular collagenous fibers on TGF-beta induced NRK-49F cells, and has inhibition on migration of HUVEC cells; and the compound with the structure has a certain curative effect on carbon tetrachloride induced hepatic fibrosis and bleomycin induced pulmonary fibrosis mouse models, is relatively low in toxicity, and provides a new choice forclinical treatment of tissue fibrosis diseases including hepatic fibrosis, pulmonary fibrosis and renal fibrosis.

Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway

Idiopathic pulmonary fibrosis (IPF) is a progressive, life-threatening and interstitial lung disease with the median survival of only 3–5 years. However, due to the unclear etiology and problems in accurate diagnosis, up to now only two drugs were approved by FDA for the treatment of IPF and their outcome responses are limited. Numerous studies have shown that TGF-β is the most important cytokine in the development of pulmonary fibrosis and plays a role through its downstream signaling molecule TGF-binding receptor Smads protein. In this paper, compounds bearing 2(1H)-quinolone scaffold were designed and their anti-fibrosis effects were evaluated. Of these compounds, 20f was identified as the most active one and could inhibit TGF-β-induced collagen deposition of NRK-49F cells and mouse fibroblasts migration with comparable activity and lower cytotoxicity than nintedanib in vitro. Further mechanism studies indicated that 20f reduced the expression of fibrogenic phenotypic protein α-SMA and collagen Ⅰ by inhibiting the TGF-β/Smad dependent pathways and ERK1/2 and p38 pathways. Moreover, compared with the nintedanib, 20f (100 mg/kg/day, p.o) more effectively alleviated collagen deposition in lung tissue and delayed the destruction of lung tissue structure both in bleomycin-induced prevention and treatment mice pulmonary fibrosis models. The immunohistochemical experiments further showed that 20f could block the expression level of phosphorylated Smad3 in the lung tissue cells, which resulted in its anti-fibrosis effects in vivo. In addition, 20f demonstrated good bioavailability (F = 41.55% vs 12%, compare with nintedanib) and an appropriate elimination half-life (T1/2 = 3.5 h), suggesting that 20f may be a potential drug candidate for the treatment of pulmonary fibrosis.

Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells

Cell division cycle phosphatases CDC25 A, B and C are involved in modulating cell cycle processes and are found overexpressed in a large panel of cancer typology. Here, we describe the development of two novel quinone-polycycle series of CDC25A and C inhi

Regioselective Alkoxydehalogenation of 2,4-Dihalogenoquinolines and a Reinvestigation of the Bromination of 2-Methoxyquinoline

Regioselective alkoxydehalogenation of 2,4-dichloro- and 2,4-dibromo-quinoline with solid sodium alkoxide in toluene gives the 2-alkoxy-4-halogenoquinolines 7-10, identified by 1H and 13C NMR spectroscopy.Bromination of 2-methoxyquinoline occurs at the 6- and 8-positions and does not give the 4-bromo derivative as originally reported.